Literature DB >> 28868349

Tumor-initiating CD49f cells are a hallmark of chemoresistant triple negative breast cancer.

Jorge Gomez-Miragaya1, Eva González-Suárez1.   

Abstract

Taxanes are mainstay treatment of triple negative breast cancer (TNBC) patients but resistance often develops. Using TNBC patient-derived orthoxenografts (PDX) we have recently discovered that a CD49f+ chemoresistant population with tumor-initiating ability is present in sensitive tumors and expands in tumors that have acquired resistance. Importantly, sensitivity to taxanes is recovered after long-term drug interruption. The characterization of this chemoresistant CD49f+ cells provides a unique opportunity to identify novel targets for the treatment of chemoresistant TNBC.

Entities:  

Keywords:  CD49f tumor-initiating cells; PDX (patient-derived orthoxenografts); chemoresistance; docetaxel; triple negative breast cancer (TNBC)

Year:  2017        PMID： 28868349      PMCID： PMC5540214          DOI： 10.1080/23723556.2017.1338208

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  8 in total

1.  Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  E Senkus; S Kyriakides; S Ohno; F Penault-Llorca; P Poortmans; E Rutgers; S Zackrisson; F Cardoso
Journal:  Ann Oncol       Date:  2015-09       Impact factor: 32.976

2.  Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.

Authors:  Chong Sun; Liqin Wang; Sidong Huang; Guus J J E Heynen; Anirudh Prahallad; Caroline Robert; John Haanen; Christian Blank; Jelle Wesseling; Stefan M Willems; Davide Zecchin; Sebastijan Hobor; Prashanth K Bajpe; Cor Lieftink; Christina Mateus; Stephan Vagner; Wipawadee Grernrum; Ingrid Hofland; Andreas Schlicker; Lodewyk F A Wessels; Roderick L Beijersbergen; Alberto Bardelli; Federica Di Nicolantonio; Alexander M M Eggermont; Rene Bernards
Journal:  Nature       Date:  2014-03-26       Impact factor: 49.962

Review 3.  Interrogating open issues in cancer precision medicine with patient-derived xenografts.

Authors:  Annette T Byrne; Denis G Alférez; Frédéric Amant; Daniela Annibali; Joaquín Arribas; Andrew V Biankin; Alejandra Bruna; Eva Budinská; Carlos Caldas; David K Chang; Robert B Clarke; Hans Clevers; George Coukos; Virginie Dangles-Marie; S Gail Eckhardt; Eva Gonzalez-Suarez; Els Hermans; Manuel Hidalgo; Monika A Jarzabek; Steven de Jong; Jos Jonkers; Kristel Kemper; Luisa Lanfrancone; Gunhild Mari Mælandsmo; Elisabetta Marangoni; Jean-Christophe Marine; Enzo Medico; Jens Henrik Norum; Héctor G Palmer; Daniel S Peeper; Pier Giuseppe Pelicci; Alejandro Piris-Gimenez; Sergio Roman-Roman; Oscar M Rueda; Joan Seoane; Violeta Serra; Laura Soucek; Dominique Vanhecke; Alberto Villanueva; Emilie Vinolo; Andrea Bertotti; Livio Trusolino
Journal:  Nat Rev Cancer       Date:  2017-01-20       Impact factor: 60.716

Review 4.  Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents.

Authors:  F André; C C Zielinski
Journal:  Ann Oncol       Date:  2012-08       Impact factor: 32.976

5.  Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance.

Authors:  Meghna Das Thakur; Fernando Salangsang; Allison S Landman; William R Sellers; Nancy K Pryer; Mitchell P Levesque; Reinhard Dummer; Martin McMahon; Darrin D Stuart
Journal:  Nature       Date:  2013-01-09       Impact factor: 49.962

Review 6.  Patient-derived xenograft (PDX) models in basic and translational breast cancer research.

Authors:  Lacey E Dobrolecki; Susie D Airhart; Denis G Alferez; Samuel Aparicio; Fariba Behbod; Mohamed Bentires-Alj; Cathrin Brisken; Carol J Bult; Shirong Cai; Robert B Clarke; Heidi Dowst; Matthew J Ellis; Eva Gonzalez-Suarez; Richard D Iggo; Peter Kabos; Shunqiang Li; Geoffrey J Lindeman; Elisabetta Marangoni; Aaron McCoy; Funda Meric-Bernstam; Helen Piwnica-Worms; Marie-France Poupon; Jorge Reis-Filho; Carol A Sartorius; Valentina Scabia; George Sflomos; Yizheng Tu; François Vaillant; Jane E Visvader; Alana Welm; Max S Wicha; Michael T Lewis
Journal:  Cancer Metastasis Rev       Date:  2016-12       Impact factor: 9.264

7.  ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†.

Authors:  F Cardoso; A Costa; L Norton; E Senkus; M Aapro; F André; C H Barrios; J Bergh; L Biganzoli; K L Blackwell; M J Cardoso; T Cufer; N El Saghir; L Fallowfield; D Fenech; P Francis; K Gelmon; S H Giordano; J Gligorov; A Goldhirsch; N Harbeck; N Houssami; C Hudis; B Kaufman; I Krop; S Kyriakides; U N Lin; M Mayer; S D Merjaver; E B Nordström; O Pagani; A Partridge; F Penault-Llorca; M J Piccart; H Rugo; G Sledge; C Thomssen; L Van't Veer; D Vorobiof; C Vrieling; N West; B Xu; E Winer
Journal:  Ann Oncol       Date:  2014-09-18       Impact factor: 32.976

8.  Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population.

Authors:  Jorge Gómez-Miragaya; Marta Palafox; Laia Paré; Guillermo Yoldi; Irene Ferrer; Sergi Vila; Patricia Galván; Pasquale Pellegrini; Hector Pérez-Montoyo; Ana Igea; Purificación Muñoz; Manel Esteller; Angel R Nebreda; Ander Urruticoechea; Idoia Morilla; Sonia Pernas; Fina Climent; María Teresa Soler-Monso; Ana Petit; Violeta Serra; Aleix Prat; Eva González-Suárez
Journal:  Stem Cell Reports       Date:  2017-04-27       Impact factor: 7.765
  8 in total
  6 in total

Review 1.  Reporters of Cancer Stem Cells as a Tool for Drug Discovery.

Authors:  Amrutha Mohan; Reshma Raj R; Gayathri Mohan; Padmaja K P; Tessy Thomas Maliekal
Journal:  Front Oncol       Date:  2021-04-22       Impact factor: 6.244

2.  BMP4 enhances anoikis resistance and chemoresistance of breast cancer cells through canonical BMP signaling.

Authors:  Renu Sharma; Gayatri Gogoi; Snigdha Saikia; Amit Sharma; Deep Jyoti Kalita; Anupam Sarma; Anil Mukund Limaye; Manish Kumar Gaur; Jina Bhattacharyya; Bithiah Grace Jaganathan
Journal:  J Cell Commun Signal       Date:  2021-10-04       Impact factor: 5.908

3.  Human-derived osteoblast-like cells and pericyte-like cells induce distinct metastatic phenotypes in primary breast cancer cells.

Authors:  Vera Mayo; Annie C Bowles; Laura E Wubker; Ismael Ortiz; Albert M Cordoves; Richard J Cote; Diego Correa; Ashutosh Agarwal
Journal:  Exp Biol Med (Maywood)       Date:  2020-11-19

Review 4.  Markers and Reporters to Reveal the Hierarchy in Heterogeneous Cancer Stem Cells.

Authors:  Amrutha Mohan; Reshma Raj Rajan; Gayathri Mohan; Padmaja Kollenchery Puthenveettil; Tessy Thomas Maliekal
Journal:  Front Cell Dev Biol       Date:  2021-06-03

Review 5.  The Role of Steroid Hormones in Breast and Effects on Cancer Stem Cells.

Authors:  Denis G Alferez; Bruno M Simões; Sacha J Howell; Robert B Clarke
Journal:  Curr Stem Cell Rep       Date:  2018-03-13

Review 6.  Cancer Stem Cells-Origins and Biomarkers: Perspectives for Targeted Personalized Therapies.

Authors:  Lia Walcher; Ann-Kathrin Kistenmacher; Huizhen Suo; Reni Kitte; Sarah Dluczek; Alexander Strauß; André-René Blaudszun; Tetyana Yevsa; Stephan Fricke; Uta Kossatz-Boehlert
Journal:  Front Immunol       Date:  2020-08-07       Impact factor: 7.561
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.